Astrazeneca PLC (AZN) Position Reduced by Willingdon Wealth Management
Willingdon Wealth Management decreased its stake in shares of Astrazeneca PLC (NYSE:AZN) by 48.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,532 shares of the company’s stock after selling 86,896 shares during the period. Astrazeneca PLC makes up about 1.2% of Willingdon Wealth Management’s holdings, making the stock its 22nd largest position. Willingdon Wealth Management’s holdings in Astrazeneca PLC were worth $3,120,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the stock. Parallel Advisors LLC increased its stake in shares of Astrazeneca PLC by 54.3% in the second quarter. Parallel Advisors LLC now owns 6,985 shares of the company’s stock valued at $211,000 after buying an additional 2,459 shares during the last quarter. First Interstate Bank increased its stake in shares of Astrazeneca PLC by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock valued at $175,000 after buying an additional 480 shares during the last quarter. Oliver Luxxe Assets LLC increased its stake in shares of Astrazeneca PLC by 2.9% in the second quarter. Oliver Luxxe Assets LLC now owns 122,519 shares of the company’s stock valued at $4,177,000 after buying an additional 3,434 shares during the last quarter. Federated Investors Inc. PA increased its stake in shares of Astrazeneca PLC by 3.6% in the second quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock valued at $152,885,000 after buying an additional 156,256 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Astrazeneca PLC during the second quarter valued at $6,917,000. Hedge funds and other institutional investors own 14.30% of the company’s stock.
Astrazeneca PLC (NYSE:AZN) traded down 0.78% during midday trading on Friday, reaching $29.24. The company had a trading volume of 2,194,384 shares. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The stock has a market cap of $74.04 billion, a P/E ratio of 19.18 and a beta of 0.74. The firm has a 50-day moving average of $31.08 and a 200-day moving average of $31.53. Astrazeneca PLC also was the recipient of some unusual options trading activity on Wednesday. Stock traders bought 8,259 put options on the company. This represents an increase of 1,510% compared to the average daily volume of 513 put options.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s revenue for the quarter was down 9.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.83 EPS. On average, equities analysts expect that Astrazeneca PLC will post $1.86 EPS for the current fiscal year.
The company also recently declared a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a dividend of $0.44 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 44.92%.
Several analysts recently weighed in on the company. Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub downgraded Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Pareto Securities upgraded Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Morgan Stanley downgraded Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the stock. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus target price of $33.39.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.